In order to identify breast cancer subgroups that could potentially benefit from such a strategy, we analysed the relationships between SASH1 expression, genomic status and clinicopathologic parameters in three large breast tumour cohorts, identifying significant but subtype-dependent relationships between SASH1 expression, relapse and survival. Here, SASH1 is linked to breast cancer.